The therapeutic effects observed for Nimotuzumab in patients with head and neck squamous cell carcinoma [33-35], pancreatic cancer [36], non-small cell lung cancer [37] and glioma [38-40] have been characterized by the induction of a long-term stable disease with a very low toxicity profile, in contrast to other anti-EGFR agents [32,41]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.